Effect of Tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells

Anticancer Research

Volumn 17, Issue 1 A, 1997, Pages 135-140

  Chetrite, G ^a   Kloosterboer, H J ^b   Pasqualini, J R ^a  

^a Hormones and Cancer Research Unit   (France)

^b NV ORGANON   (Netherlands)

Author keywords

19 nortestosterone derivatives; Estrone sulphatase; Mammary cancer cells

Indexed keywords

DRUG METABOLITE; ESTRADIOL; ESTRONE SULFATE; NORETHISTERONE; ORG 30126; ORG 4094; ORG OM38; SULFATASE; TIBOLONE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; NORPREGNENES; SULFATASES; TUMOR CELLS, CULTURED;

EID: 0031050931     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Segaloff A: Hormones and mammary carcinogenesis. In: Breast Cancer 2: Advances in research and treatment - experimental biology (McGuire WL, ed). New York, Plenum Press, 1978, pp 1-22.
2. Henderson IC and Cannellos GP: Cancer of the breast: the last decade. New Engl J Med 302: 17-30, 1980.
3. Dao TL, Haves C and Libby PR: Steroid sulfatase activities in human breast tumors. Proc Soc Expl Biol Med 146: 381-384, 1974.
4. Tseng L, Mazella J, Lee LY and Stone ML: Estrogen sulfatase and estrogen sulfotransferase in human primary mammary carcinoma. J Steroid Biochem 19: 1413-1417, 1983.
5. Vignon F, Terqui M, Westley B, Derocq D and Rochefort H: Effects of plasma estrogen sulfates in mammary cancer cells. Endocrinology 106: 1079-1086, 1980.
6. Pasqualini JR, Gelly C and Lecerf F: Biological effects and morphological responses to estriol, estriol-3-sulfate, estriol-17-sulfate and tamoxifen in a tamoxifen-resistant cell line (R-27) derived from MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol 22: 1495- 1501, 1986.
7. Pasqualini JR, Gelly C, Nguyen B-L and Vella C: Importance of estrogen sulfates in breast cancer. J Steroid Biochem 34: 155-363, 1989.
8. Pasqualini JR, Schatz B, Varin C and Nguyen B-L: Recent data on estrogen sulfatases and sulfotransferases activities in human breast cancer. J Steroid Biochem Molec Biol 41: 323-329, 1992.
9. Perel E, Wilkins D and Killinger DW: The conversion of androstenedione to estrone, estradiol, and testosterone in breast tissue. J Steroid Biochem 13: 89-94, 1980.
10. Silva MC, Rowlands MG, Dowsett M, Gusterson B, McKinna JA, Fryatt I and Coombes RC: Intratumoral aromatase as a prognostic factor in human breast carcinoma. Cancer Res 49: 2588-2591, 1989.
11. Abul-Hajj YJ: Relationship between estrogen receptors, 17β- hydroxysteroid dehydrogenase and estrogen content in human breast cancer. Steroids 34: 217-225, 1979.
12. Vermeulen A, Deslypere JP, Paridaens R, Leclercq G, Roy F and Heuson JC: Aromatase, 17β-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol 22: 515-525, 1986.
13. Santner SJ, Feil PD and Santen RJ: In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J Clin Endocr Metab 59: 29-33, 1984.
14. Pasqualini JR, Chetrite G, Blacker C, Feinstein M-C, Delalonde L, Talbi M and Maloche C: Concentration of estrone, estradiol, estrone sulfate, and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endocr Metab 81: 1460-1464, 1996.
15. Pasqualini JR and Gelly C: Biological response of the antiestrogen ICI 164,384 in human hormone-dependent and hormone-independent mammary cancer cell lines. Cancer Lett 50: 133-139, 1990.
16. Pasqualini JR and Nguyen B-L: Estrone sulfatase activity and effect of antiestrogens on transformation of estrone sulfate in hormone- dependent vs. -independent human breast cancer cell lines. Breast Cancer Res Treat 18: 93-98, 1991.
17. Pasqualini JR, Varin C and Nguyen B-L: Effect of the progestagen R5020 (Promegestone) and of progesterone on the uptake and on the transformation of estrone sulfate in the MCF-7 and T-47D human mammary cancer cells. Correlation with progesterone receptor levels. Cancer Lett 66: 55-60, 1992.
18. Nguyen B-L, Ferme I, Chetrite G and Pasqualini JR: Action of Danazol on the conversion of estrone sulfate to estradiol and on the sulfatase activity in the MCF-7, T-47D and MDA-MB-231 human mammary cancer cells. J Steroid Biochem Molec Biol 46: 17-23, 1993.
19. Visser de J, Coert A Feenstra H and Vies van der J: Endocrinal studies with (7α,17α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD14). Arzneim Forsch Drug Res 34: 1010-1017, 1984.
20. Schot LPC, Kloosterboer HJ and Deckers GHJ: Pharmacological profile of Org OD 14 in experimental animals. In: Livial - The Current Status of Research and Therapy. Proceedings of a Symposium held at the 6th International Congress on the Menopause (Bangkok, October 1990). The Parthenon Publishing Group. Carnforth, England, 1992, pp 11-24.
21. Tax L, Goorissen EM and Kicovic PM: Clinical profile of Org OD14. Maturitas I (suppl.): 3-13, 1987.
22. Aloysio de D, Fabiani AG, Mauloni M and Bottiglioni F: Use of Org OD 14 for the treament of climacteric complaints. Maturitas (suppl.): 49-65, 1987.
23. Tang B, Markiewicz L, Kloosterboer HJ and Gurpide E: Human endometrial 3β-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic / progestagenic activity ratios of a steroidal drug (Org OD 14). J Steroid Biochem Molec Biol 45: 345-351, 1993.
24. Markiewicz L and Gurpide E: In vitro evaluation of estrogenic, estrogen antagonistic and progestagenic effects of a steroidal drug (Org OD14) and its metabolites on human endometrium. J Steroid Biochem Molec Biol 35: 535-541, 1990.
25. Plu-Bureau G, Lê MG, Sitruk-Ware R, Thalabard JC and Mauvais-Jarvis P: Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease. Br J Cancer 70: 270-277, 1994.
26. Theriault RL: Hormone replacement therapy and breast cancer: an overview. Br J Obstet Gynaecol 103 (Suppl 13): 87-91, 1996.
27. Kloosterboer HJ, Schoonen WGEJ, Deckers GH and Klijn JGM: Effects of progestagens and Org OD14 in in vitro and in vivo tumor models. J Steroid Biochem Molec Biol 49: 311-318, 1994.
28. Burton K: A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 62: 315-323, 1956.
29. Markiewicz L, Hochberg RB and Gurpide E: Intrinsic estrogenicity of some progestagenic drugs. J Steroid Biochem Molec Biol 41: 53-58, 1992.
30. Markiewicz L and Gurpide E: Estrogenic and progestagenic activities coexisting in steroidal drugs: Quantitative evaluation by in vitro bioassays with human cells. J Steroid Biochem Molec Biol 48: 89-94, 1994.
31. Perez-Palacios G, Cerbon MA, Pasapera AM, Castro JI, Enriquez J, Vilchis F, Garcia GA, Morali G and Lemus A: Mechanisms of hormonal and antihormonal action of contraceptive progestins at the molecular level. J Steroid Biochem Molec Biol 41: 479-485, 1992.
32. Jeng MH, Parker CJ and Jordan VC: Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res 52: 6539-6546, 1992.
33. Egarter C, Huber J, Leikermoser R, Haidbauer R, Pusch H, Fischl F and Putz M: Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints. Maturitas 23: 55-62, 1996.
34. Schoonen WGEJ, Joosten JWH and Kloosterboer HJ: Effects of two classes of progestagens. pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: I. MCF-7 cell lines. J Steroid Biochem Molec Biol 55: 423-437, 1995.
35. Schoonen WGEJ, Joosten JWH and Kloosterboer HJ: Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: II. T47D cell lines. J Steroid Biochem Molec Biol 55: 439-444, 1995.